secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001193125-25-308769
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026
---------------------------------------------------------------------------

- David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).
- Base salary set at $522,000; annual bonus target up to 40% of base salary.
- Receives option to purchase 375,000 shares, vesting 25% on first anniversary and monthly thereafter.
- Eligible for separation benefits under the Executive Separation Benefits and Retention Plan.
- Standard indemnification agreement to be entered with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/0001193125-25-308769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/trvi-20251201.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-308769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer